NCT06806241

Brief Summary

Tranexamic acid (TXA) is an effective hemostatic agent used to reduce blood loss and the need for transfusion. It is a relatively safe drug with minimal significant side effects. The most commonly reported complications include nausea, diarrhea, and occasional orthostatic reactions. The increased risk of thromboembolic events associated with the drug is the most serious complication; however, this has not been reported in most clinical studies and remains uncertain. Based on experience from other types of surgeries, tranexamic acid appears to be safe for use without an increased risk of venous thrombosis. To mitigate systemic absorption and minimize undesirable side effects, TXA can be applied topically rather than intravenously, reducing the risk of venous thromboembolism.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2025

Completed
26 days until next milestone

First Submitted

Initial submission to the registry

January 27, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 4, 2025

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2026

Completed
9 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 10, 2026

Completed
Last Updated

June 24, 2025

Status Verified

June 1, 2025

Enrollment Period

1.2 years

First QC Date

January 27, 2025

Last Update Submit

June 23, 2025

Conditions

Keywords

bleedingtranexamic acidwisdom teeth removaledema

Outcome Measures

Primary Outcomes (1)

  • postoperative edema

    Anatomical landmarks, including gonion (Go), ala nasi (AN), tragus (Tr), and lateral canthus (Ka), will be marked with methylene blue for measurement purposes. The distances between lateral canthus and gonion, tragus and commissure, and gonion and ala nasi will be measured preoperatively (just before the procedure begins) and on postoperative day 3, when maximum edema is expected, and the values will be recorded.

    3 days

Secondary Outcomes (2)

  • intraoperative bleeding

    during the surgery time

  • intraoperative vision scale

    during the surgery

Study Arms (2)

saline irrigation group

In the double-blind, controlled, randomized study, only saline will be used as the irrigation solution in the control group patients.

Drug: saline irrigation

tranexamic acid Irrigation group

In the double-blind, controlled, randomized study, saline with tranexamic acid solution will be used as the irrigation solution in the study group patients.

Drug: Tranexamic acid

Interventions

in the study group, a combination of two ampules of Tranexamic acid solution mixed with saline will be used. Intraoperative bleeding, surgical field visibility, and postoperative edema will be monitored.

tranexamic acid Irrigation group

In control group, saline will be used for irrigation.Intraoperative bleeding, surgical field visibility, and postoperative edema will be monitored.

saline irrigation group

Eligibility Criteria

Age14 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodProbability Sample
Study Population

community sample

You may qualify if:

  • Indicated for the Extraction of Bilaterally Impacted Third Molars with Bone Retention.
  • Systemically healthy patients aged 14-40 years with no bleeding disorders.

You may not qualify if:

  • Patients with systemic diseases affecting general health.
  • Patients diagnosed with any bleeding disorder.
  • Patients with advanced infection or cysts associated with the impacted tooth.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bezmialem Vakıf Universty

Istanbul, Fatih, 34093, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

HemorrhageEdema

Interventions

Tranexamic Acid

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsSigns and Symptoms

Intervention Hierarchy (Ancestors)

Cyclohexanecarboxylic AcidsAcids, CarbocyclicCarboxylic AcidsOrganic Chemicals

Central Study Contacts

Taha Pergel, Asist.Prof

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
3 Days
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 27, 2025

First Posted

February 4, 2025

Study Start

January 1, 2025

Primary Completion

March 1, 2026

Study Completion

March 10, 2026

Last Updated

June 24, 2025

Record last verified: 2025-06

Locations